Frances Loftus, DO
Pulmonary Disease · Galloway, NJNPI 1851381438
Payments from drug & device makers
Across 545 payments — averaging $141.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$59K
- AbbVie$12K
- Boehringer Ingelheim$3K
- AstraZeneca$886
- Mylan Specialty L.p.$739
- Regeneron Healthcare Solutions, Inc.$406
- plus $2K from 24 others
What the payments were for
- Consulting fees$7301%
- Speaking & faculty fees$64,32083%
- Travel & lodging$4,1045%
- Food & beverage$8,17911%
- Education$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 191 | $59,009 |
| AbbVie(2 entities) | 48 | $11,665 |
| Boehringer Ingelheim | 42 | $2,707 |
| AstraZeneca | 53 | $886 |
| Mylan Specialty L.p. | 68 | $739 |
| Regeneron Healthcare Solutions, Inc. | 19 | $406 |
| Philips North America LLC | 17 | $278 |
| Sanofi | 17 | $276 |
| Actelion Pharmaceuticals US, Inc. | 16 | $242 |
| Grifols USA, LLC | 8 | $127 |
| Genentech USA, Inc. | 9 | $121 |
| Insmed, Inc. | 7 | $115 |
| Amgen | 6 | $112 |
| Harmony Biosciences LLC | 5 | $101 |
| Avadel CNS Pharmaceuticals, LLC | 6 | $98 |
| Novartis | 4 | $71 |
| Jazz Pharmaceuticals Inc. | 4 | $62 |
| Verona Pharma, Inc. | 3 | $54 |
| United Therapeutics Corporation | 3 | $50 |
| Bayer | 3 | $47 |
| Electromed, Inc. | 3 | $44 |
| Merck | 3 | $40 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $29 |
| Sunovion Pharmaceuticals Inc. | 2 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Portola Pharmaceuticals, LLC | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$77,379 in reported general payments places this provider in the 95th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 21 | $291,795 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 207 | $193,734 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 81 | $95,262 |
| Breo ElliptaFluticasone/Vilanterol | 91 | $47,431 |
| Spiriva RespimatTiotropium Bromide | 60 | $44,308 |
| Incruse ElliptaUmeclidinium Bromide | 48 | $20,459 |
| EliquisApixaban | 21 | $20,003 |
| SymbicortBudesonide/Formoterol Fumarate | 46 | $17,471 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $15,891 |
| Arnuity ElliptaFluticasone Furoate | 36 | $12,074 |
| AlvescoCiclesonide | 19 | $11,108 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $10,210 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 46 | $8,736 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 203 | $8,650 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $7,481 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $2,707 | $346,313100 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $59,009 | $289,589410 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $886 | $112,733127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Galloway
- Salaam AlobeidyGalloway$15K
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Sabina HussainNew Brunswick$555K
- Manuel CunananMillville$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.